Recent developments in bioprocessing of recombinant proteins: expression hosts and process development

NK Tripathi, A Shrivastava - Frontiers in Bioengineering and …, 2019 - frontiersin.org
Infectious diseases, along with cancers, are among the main causes of death among
humans worldwide. The production of therapeutic proteins for treating diseases at large …

Trends in upstream and downstream process development for antibody manufacturing

P Gronemeyer, R Ditz, J Strube - Bioengineering, 2014 - mdpi.com
A steady increase of product titers and the corresponding change in impurity composition
represent a challenge for development and optimization of antibody production processes …

Recent advances in large-scale production of monoclonal antibodies and related proteins

AA Shukla, J Thömmes - Trends in biotechnology, 2010 - cell.com
The rapid development of high-yielding and robust manufacturing processes for monoclonal
antibodies is an area of significant focus in the biopharmaceutical landscape. Advances in …

Advances in the production and downstream processing of antibodies

JH Chon, G Zarbis-Papastoitsis - New biotechnology, 2011 - Elsevier
Sales of monoclonal antibody (mAbs) therapies exceeded
40billionin2010andareexpectedtoreach 70 billion by 2015. The majority of the approved …

Guidelines to cell engineering for monoclonal antibody production

AR Costa, ME Rodrigues, M Henriques… - European Journal of …, 2010 - Elsevier
Monoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic
applications. The high demand for these biopharmaceuticals has led to the development of …

Economic analysis of batch and continuous biopharmaceutical antibody production: A review

O Yang, M Qadan, M Ierapetritou - Journal of pharmaceutical innovation, 2020 - Springer
Purpose There is a growing interest in continuous biopharmaceutical processing due to the
advantages of small footprint, increased productivity, consistent product quality, high …

Accelerating biologics manufacturing by modeling or: is approval under the QbD and PAT approaches demanded by authorities acceptable without a digital-twin?

S Zobel-Roos, A Schmidt, F Mestmäcker, M Mouellef… - Processes, 2019 - mdpi.com
Innovative biologics, including cell therapeutics, virus-like particles, exosomes, recombinant
proteins, and peptides, seem likely to substitute monoclonal antibodies as the main …

Microfluidic cell retention device for perfusion of mammalian suspension culture

T Kwon, H Prentice, JD Oliveira, N Madziva… - Scientific reports, 2017 - nature.com
Continuous production of biologics, a growing trend in the biopharmaceutical industry,
requires a reliable and efficient cell retention device that also maintains cell viability. Current …

Technological progresses in monoclonal antibody production systems

ME Rodrigues, AR Costa, M Henriques… - Biotechnology …, 2010 - Wiley Online Library
Monoclonal antibodies (mAbs) have become vitally important to modern medicine and are
currently one of the major biopharmaceutical products in development. However, the high …

Process analytical technology as key‐enabler for digital twins in continuous biomanufacturing

A Schmidt, H Helgers, LJ Lohmann… - Journal of Chemical …, 2022 - Wiley Online Library
Over the last few years rapid progress has been made in adopting well‐known process
modeling techniques from chemicals to biologics manufacturing. The main challenge has …